Conmed (NYSE: CNMD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Conmed reported 1 open-market sale of 257 shares ($10,591) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 November 2026 | Foust Hollie K | General Counsel & Corp Sec | Option exercise | +4,000 | — | 6,886 | Form 4 |
| 4 November 2026 | Foust Hollie K | General Counsel & Corp Sec | Shares withheld for tax | −1,124 | $53.66 | 5,762 | Form 4 |
| 8 September 2026 | Kelderman Kim | Director | Option exercise | +500 | — | 500 | Form 4 |
| 2 June 2026 | Schwarzentraub Barbara J | Director | Option exercise | +668 | — | 5,012 | Form 4 |
| 2 June 2026 | Kaye Mark | Director | Option exercise | +668 | — | 820 | Form 4 |
| 2 June 2026 | Farkas Charles | Director | Option exercise | +668 | — | 15,527 | Form 4 |
| 2 June 2026 | Council LaVerne H | Director | Option exercise | +668 | — | 4,716 | Form 4 |
| 2 June 2026 | Bronson David M. | Director | Option exercise | +668 | — | 17,909 | Form 4 |
| 6 March 2026 | Lalomia Brent | Executive VP RA, QA | Option exercise | +75 | — | 941 | Form 4 |
| 6 March 2026 | Lalomia Brent | Executive VP RA, QA | Shares withheld for tax | −26 | $39.90 | 915 | Form 4 |
| 24 February 2026 | Kaye Mark | Director | Option exercise | +152 | — | 152 | Form 4 |
| 21 November 2025 | Glaze Richard | Chief Information Officer | Open-market sale, 10b5-1 plan | −257 | $41.21 | 0 | Form 4 |
| 20 November 2025 | Glaze Richard | Chief Information Officer | Option exercise | +375 | — | 375 | Form 4 |
| 20 November 2025 | Glaze Richard | Chief Information Officer | Shares withheld for tax | −118 | $40.63 | 257 | Form 4 |
| 6 November 2025 | Garner Todd W | Executive Vice President & CFO | Open-market sale, 10b5-1 plan | −3,500 | $43.00 | 1,836 | Form 4 |
| 4 November 2025 | Foust Hollie K | General Counsel & Corp Sec | Option exercise | +4,000 | — | 4,000 | Form 4 |
| 4 November 2025 | Foust Hollie K | General Counsel & Corp Sec | Shares withheld for tax | −1,114 | $45.71 | 2,886 | Form 4 |
| 31 October 2025 | Garner Todd W | Executive Vice President & CFO | Option exercise | +7,500 | — | 7,500 | Form 4 |
| 31 October 2025 | Garner Todd W | Executive Vice President & CFO | Shares withheld for tax | −2,164 | $44.00 | 5,336 | Form 4 |
| 12 September 2025 | Farkas Charles | Director | Open-market sale | −1,103 | $53.54 | 15,756 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Conmed page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.